General
Preferred name
RALTEGRAVIR
Synonyms
MK-0518 ()
MK 0518 potassium salt ()
Raltegravir potassium salt ()
Raltegravir (MK-0518) ()
RALTEGRAVIR POTASSIUM ()
Raltegravir (potassium) ()
MK 0518 (potassium) ()
MK-0518 potassium ()
Raltegravir (potassium salt) ()
Raltegravir monopotassium salt ()
Isentress ()
L-000900612 POTASSIUM SALT ()
Isentress hd ()
L000900612 POTASSIUM SALT ()
Raltegravir potassium component of dutrebis ()
MK0518 POTASSIUM ()
L-000900612 ()
L000900612 ()
Raltegravir-d4 ()
P&D ID
PD009217
CAS
871038-72-1
518048-05-0
2712343-38-7
Tags
available
drug
Approved by
FDA
PMDA
EMA
First approval
2007
Drug indication
viral disease
HIV infection
Human immunodeficiency virus infection
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.
PRICE 29
MOA Raltegravir inhibits HIV integrase to prevent the viral genome being incorporated into the human genome. Raltegravir is primarily metabolized by glucuronidation.
DESCRIPTION Raltegravir (MK-0518) is an HIV integrase inhibitor (integrase strand transfer inhibitor) . (GtoPdb)
DESCRIPTION Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection.
PRICE 95
DESCRIPTION Raltegravir potassium (MK 0518 potassium salt) salt(MK0518 potassium salt) is a potent integrase (IN) inhibitor, used to treat HIV infection. (TargetMol Bioactive Compound Library)
DESCRIPTION Raltegravir is a potent integrase (IN) inhibitor. Raltegravir is an antiretroviral drug used for the treatment of HIV-1 infection in conjunction with other antiretrovirals. (Enamine Bioactive Compounds)
DESCRIPTION Raltegravir (MK-0518) is a pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
4
Compound Sets
25
AdooQ Bioactive Compound Library
A10775
A21403
Axon Medchem Screening Library
3120
Cayman Chemical Bioactives
16071
26458
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL518520
CHEMBL254316
ChEMBL Drugs
CHEMBL518520
CHEMBL254316
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB06817
DrugBank Approved Drugs
DB06817
DrugCentral
2352
DrugCentral Approved Drugs
2352
DrugMAP
DMYURI6
DrugMAP Approved Drugs
DMYURI6
Enamine Bioactive Compounds
EBC-07544
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS100143
Guide to Pharmacology
11571
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL254316
MedChem Express Bioactive Compound Library
HY-10353A
HY-10353
NCATS Inxight Approved Drugs
22VKV8053U
ReFrame library
Selleckchem Bioactive Compound Library
raltegravir-potassium
Raltegravir-(MK-0518)
TargetMol Bioactive Compound Library
T2239
T2239L
VGSC-DB
NA1594
NA1595
External IDs
58
Properties
(calculated by RDKit )
Molecular Weight
444.16
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
3
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
3
cLogP
0.91
TPSA
152.24
Fraction CSP3
0.3
Chiral centers
0.0
Largest ring
6.0
QED
0.51
QED
0.51
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
viral integrase inhibitor
HIV Protease inhibitor
Integrase inhibitor
HIV integrase inhibitor
Target
Gag-Pol polyprotein
Human immunodeficiency virus type 1 integrase
Integrase
HIV
HIV Integrase
Integrase (S217Q PFV)
Integrase (WT PFV)
Integrase (IN)
Pathway
Microbiology/virology
Proteases/Proteasome
Anti-infection
Metabolic Enzyme/Protease
Indication
human immunodeficiency virus (HIV-1)
VGSC Target
Nav1.5
Source data